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Organophosphate (OP) compounds exert inhibition on cholinesterase (ChE) activity by irreversibly bind-
ing to the catalytic site of the enzyme. Oximes are compounds generally used to reverse the ChE inhibi-
tion caused by OP agents. In this study, we compared the in vitro reactivation potency of two new oximes
(oxime 1: butane-2,3-dionethiosemicarbazone; oxime 2: 3-(phenylhydrazono) butan-2-one) against the
inhibition on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities induced by chlor-
pyrifos, diazinon and malathion. Oximes used clinically (obidoxime and pralidoxime) were used as posi-
tive control. For this study, human blood (erythrocytes for AChE determination and plasma for BChE
determination) was used and different concentrations of oximes (1–100 lM) were tested. The concentra-
tions of OP used were based on the IC50 for AChE and BChE. Results demonstrated that obidoxime was
more effective in reactivate the AChE inhibition induced by OP compounds. However, both newly devel-
oped oximes achieved similar reactivations rates that pralidoxime for chlorpyrifos and diazinon-inhibited
AChE. For BChE reactivation, none of evaluated oximes achieved positives rates of reactivation, been obi-
doxime able to reactivate malathion-inhibited BChE only in 24% at the highest concentration. We con-
clude that both newly developed oximes seem to be promising reactivators of OP-inhibited AChE.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction The search for oxime-based reactivators dates back to the earlyIn Brazil the exposure to pesticides like organophosphate (OP)
compounds represents an important problem with respect to hu-
man health (Brocardo et al., 2007). OPs are one speciﬁc group of
the cholinesterase inhibitors. Among them, the so-called ‘nerve
agents’ are considered the most toxic substances yet synthesized
(Marrs, 1993). The toxic action of OP nerve agents and pesticides
is related to the binding of these compounds to the active site of
the acetylcholinesterase enzyme (AChE; EC 3.1.1.7) thus inhibiting
its physiologic action of hydrolyzing the acetylcholine (ACh) neu-
rotransmitter at central and peripheral synapses (Taylor et al.,
1995). ACh accumulation results in an over-stimulation of cholin-
ergic receptors and, depending on the type and dose of the incor-
porated OP, in a disturbance of numerous body functions and
ﬁnally in respiratory arrest and death (Worek et al., 2007).Análises Clínicas e Toxicoló-
deral de Santa Maria, Santa
140; fax: +55 55 3220 8978.
andão).
sevier OA license.1950s, starting with hydroxylamine and hydroxamic acids (Hobbi-
ger, 1993). Later on, ketoximes and aldoximes were investigated.
Meanwhile, more than 1500 compounds have been tested, how-
ever, only few have been studied for human use. The most well-
known and currently available AChE reactivators are of insufﬁcient
potency in case of intoxication by several nerve agents. Conse-
quently, many new AChE reactivators are still synthesized and
tested throughout the world (Kuca et al., 2010). Determination of
erythrocyte AChE activity and cholinesterase status are no stan-
dard laboratory assays. However, determination of plasma butyr-
ylcholinesterase (BChE; EC 3.1.1.8) is used for monitoring of OP
poisoning and for the assessment of oxime beneﬁt (Eddleston
et al., 2008). Compared to AChE, BChE may show different inhibi-
tion, reactivation and aging kinetics (Eyer, 2003). Hence, the value
of BChE as therapeutic marker in OP poisoning is questionable.
In this way, in the current study we will test two new oximes
with antioxidants properties (Portella et al., 2008; Puntel et al.,
2008, 2009) as reactivators of chlorpyrifos, diazinon and mala-
thion-inhibitedAChE andBChE in vitro. Indeed, to obtain some com-
parison with currently available accepted AChE reactivators, we
have included the known reactivators pralidoxime and obidoxime.
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2.1. Synthesis of oximes
The butane-2,3-dionethiosemicarbazone oxime (oxime 1) was
prepared by the mixture of 1 mol diacetylmonoxime with 1 mol of
thiosemicarbazide both dissolved in ethanol, and made acid by the
addition of 0.5 ml of acetic acid 0.1 M. After 3 h of stirring and reﬂux,
a pale yellow product was formed, collected by ﬁltration, washed
with water and dried in vacuum, yield 70%, mp 225 C. IR:
m = 1595 cm1 (CfN), 1296 cm1 (CfS), 1087 cm1 (O–N), 3251 cm1
(N–H), 3420 cm1 (O–H).
The 3-(phenylhydrazono) butan-2-one oxime (oxime 2) was
prepared by a simple mixture and reﬂux for 3 h of 1 mol diacetyl-
monoxime with 1 mol of phenylhydrazine chloride both dissolved
in a mixture of ethanol–H2O (2:1, v/v) and 0.5 ml of sodium acetate
6 M. On heating, a dark orange product was formed, collected by
ﬁltration, washed with water, and dried in vacuum (yield 70%,
mp 190 C).
2.2. Chemicals
Pralidoxime (2-PAM; 1-methyl-2-hydroxyiminomethylpyridi-
nium chloride) and Obidoxime (1,3-bis (4-hydroxyiminomethylpy-
ridinium)-2-oxapropane dichloride) were purchased from Sigma–
Aldrich (Brazil). Chlorpyrifos (O,O-diethyl O-3,5,6-trichloropyri-
din-2-yl phosphorothioate) was purchased from La Forja S.A.
(Montevideo, Uruguay); Diazinon (O,O-diethyl O-[4-methyl-6-
(propan-2-yl) pyrimidin-2-yl] phosphorothioate) was purchased
from Lusa S.A. (Montevideo, Uruguay) and Malathion (diethyl 2-
[(dimethoxyphosphorothioyl) sulfanyl] butanedioate) was pur-
chased from Nitrosin S.A. (Curitiba, Brazil). All other chemicals
used in this study were of analytical purity and were purchased
from Sigma–Aldrich (Brazil). Structure of studied oximes and orga-
nophosphates is given in Fig. 1.
2.3. In vitro reactivation of AChE and BChE
Human blood samples were obtained from healthy volunteers.
The blood samples were collected with heparin and then centri-
fuged for 10 min at 5000 rpm. The plasma was removed as super-
natant, as source of BChE. The erythrocytes were hemolyzed in
phosphate buffer (0.1 M, pH7.4) in a ratio 1:10 (w/w), as sourceFig. 1. Chemical structures of studied oximes and organophosphates.of AChE (Jun et al., 2008). The time of enzyme inhibition with the
OP was of 1 h. The concentrations of OP used were based on the
IC50 values previously experimentally calculated (8.06; 20.72 and
73.00 lM for chlorpyrifos, diazinon and malathion-inhibited AChE,
respectively and 1.15; 1.20 and 1.80 lM for chlorpyrifos, diazinon
and malathion-inhibited BChE, respectively).
For BChE inhibition, OP solution diluted in phosphate buffer
(0.1 M, pH 7.4) was added to the plasma. The same was performed
for the inhibition of AChE only that instead of plasma a hemolyzed
solution content ethopropazine dichloride 6 mM (to avoid plasma
esterase interference) was used. After inhibition, the solution of
reactivator (ﬁnal concentrations of tested reactivators were 1, 10,
50 and 100 lM) in phosphate buffer (0.1 M, pH 7.4) was added
to the mixture containing the inhibited enzyme (AChE or BChE).
After 10 min of reactivation (Jun et al., 2008), 5,5-dithiobis-2-nitro-
benzooic acid (DTNB) in phosphate buffer (0.1 M, pH 7.4) was
added and the enzymatic reaction was initiated by addition of
acetylthiocholine (ATCh) or butyrylthiocholine (BTCh) substrates.
The ﬁnal concentration of DTNB in the mixture was 0.3 mM and
ATCh or BTCh in the mixture was 0.45 mM.
The ﬁnal volume of sample in cuvette was 1 ml. The activities of
AChE and BChE were determined for one min using the method of
Ellman et al. (1961) modiﬁed by Worek et al. (1999a) using two
different absorbance of 436 nm for AChE (to avoid hemoglobin
interference) and at 412 nm for BChE. All results were corrected
for hydrolysis of substrate by reactivators. Reactivation potency
was calculated following the next equation:
%R ¼ ð1 ½ða0  arÞ=ða0  aiÞÞ  100
where %R is percent of reactivation, a0 is activity of intact enzyme, ai
is activity of inhibited enzyme and ar is activity of reactivated en-
zyme. Each measurement was repeated eight times. All experi-
ments were conducted under standard laboratory temperature
(25 C). Calculations were performed using software GraphPad
Prism version 5.00 for Windows, GraphPad Software, San Diego,
CA, USA, www.graphpad.com.
3. Results
In this study we have made a comparative between reactivation
of organophosphate-inhibited cholinesterase rates for all tested
oximes and the results are summarized in Table 1. For chlorpyri-
fos-inhibited AChE, reactivation rates of both newly evaluated oxi-
mes were similar to those achieved by pralidoxime. Indeed, when
compared the reactivation rate between both newly evaluated oxi-
mes in the highest concentration (100 lM), they present only 1%
difference, and 5% when compared with pralidoxime. However,Table 1
Mean organophosphate-inhibited acetylcholinesterase reactivation.
1 lM 10 lM 50 lM 100 lM
Chlorpyrifos
Oxime 1 10 ± 0.016 24 ± 0.007 25 ± 0.013 27 ± 0.001
Oxime 2 7 ± 0.009 15 ± 0.011 20 ± 0.010 27 ± 0.009
Pralidoxime 10 ± 0.014 17 ± 0.041 21 ± 0.030 22 ± 0.068
Obidoxime 23 ± 0.015 67 ± 0.060 67 ± 0.040 88 ± 0.016
Diazinon
Oxime 1 20 ± 0.010 40 ± 0.058 38 ± 0.042 40 ± 0.027
Oxime 2 12 ± 0.025 53 ± 0.052 62 ± 0.036 55 ± 0.055
Pralidoxime 12 ± 0.021 61 ± 0.058 63 ± 0.021 61 ± 0.046
Obidoxime 20 ± 0.037 70 ± 0.044 74 ± 0.017 96 ± 0.050
Malathion
Oxime 1 5 ± 0.012 18 ± 0.018 17 ± 0.010 32 ± 0.013
Oxime 2 12 ± 0.019 33 ± 0.021 31 ± 0.017 31 ± 0.017
Pralidoxime 18 ± 0.030 36 ± 0.019 39 ± 0.010 61 ± 0.011
Obidoxime 14 ± 0.016 75 ± 0.002 67 ± 0.023 82 ± 0.005
Values are expressed as percentage (%) of reactivation ± SEM.
Fig. 2. Calculated reactivation of organophosphates-inhibited butyrylcholine
sterase.
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centrations; even at the smaller concentration (1 lM) obidoxime
had reactivations rates similar to those achieved at the highest
concentration for the others oximes.
For diazinon-inhibited AChE, reactivation rates of both newly
evaluated oximes did not was similar, as for chlorpyrifos-inhibited
AChE. Betters reactivation rates were achieved with oxime 2 at 10,
50 and 100 lMwhen compared with oxime 1. Indeed, oxime 2 had
similar reactivation rate at 50 lM when compared with pralidox-
ime at 10, 50 and 100 lM. Oxime 2 had a highest reactivation at
50 lM that at 100 lM, the same happens for pralidoxime at the
same concentrations, showing that there is no correlation between
oxime concentration and reactivation rate. Obidoxime at 10 lM
presented highest reactivation rates that all others oximes at
100 lM. Indeed, obidoxime at 100 lM achieved almost the 100%
of reactivation.
In malathion-inhibited AChE, both newly evaluated oximes had
similar reactivation rates at 100 lM, however, at 1, 10 and 50 lM
oxime 2 presented better results. Pralidoxime at 100 lM achieved
61% of reactivation, almost twice as oximes1 and 2 at the same
concentration. As happened for chlorpyrifos and diazinon-inhib-
ited AChE, obidoxime achieved better reactivation rates. However,
as observed in oxime 2 reactivation for diazinon-inhibited AChE, it
same that there is no correlation between oxime concentration and
reactivation rate since obidoxime at 10 lM achieved 75% of reacti-
vation and at 50 lM achieved 67%.
Results of in vitro activity of tested oximes (at 100 lM) towards
OP-inhibited BChE are summarized in Fig. 2. Obidoxime, the oxime
with better results in reactivate AChE, was able to reactivate mal-
athion-inhibited BChE only in 24% at 100 lM. Lower oximes con-
centrations were of insufﬁcient potency of reactivation (data not
shown).
4. Discussion
Since Wilson and Ginsburg (1955) discover that mono-pyridini-
um oximes were effective reactivators of OP-inhibited AChE, sev-
eral mono-pyridinium and bis-pyridinium oximes have been
synthesized and tested (Jun et al., 2008). In this study, we have
tested the potential of reactivation of two newly oximes against
chlorpyrifos, diazinon and malathion-inhibited AChE and BChE,
and compared with the currently available oximes (obidoxime
and pralidoxime). It is well known that the inhibition of AChE
and BChE activities in an organism is due the effect of the active
metabolites (oxons). Nevertheless, the practice of in vitro AChE
reactivation inhibited with the parent OP is well documented (Ach-
arya et al., 2008, 2011; Maxwell et al., 2008; Kuca et al., 2005,
2010; Worek et al., 2007) and accepted as evaluation of oximereactivation potency. In previous studies by our group, it was dem-
onstrated that these two new oximes possess antioxidant activity
against the oxidative damage induced by different oxidant agents
(Portella et al., 2008; Puntel et al., 2008, 2009). However, this is
the ﬁrst time in which these oximes are tested against OP-inhib-
ited AChE. The results here obtained showed that both new evalu-
ated oximes have similar reactivation rates for chlorpyrifos-
inhibited AChE compared to pralidoxime, and even better reactiva-
tion rates than pralidoxime for diazinon-inhibited AChE. However,
the better results were achieved with obidoxime for all tested OP.
The structure–activity relationships for oxime efﬁcacy are still
poorly understood (Kuca et al., 2006), since the potency of oxime
reactivations has a complex dependency on the nucleophilicity
and orientation of the oxime as well as on the structure of the
OP–AChE conjugate (Ashani et al., 1995). The mechanism by which
the oxime exerts AChE reactivation property is based on the chem-
ical principle that oxime reactivation occurs by the nucleophilic at-
tack of oximate anions on the OP–AChE conjugates (Wilson et al.,
1992). In this study, we tested two new oximes which have only
one aldoxime group, like pralidoxime. By the other hand, obidox-
ime has two aldoximes groups and it was this one that achieved
the better results in reactivate OP-inhibited AChE. However, Kassa
et al. (2008) had demonstrated in a previous study that the number
of aldoxime groups is not so important in enzyme reactivation. In
this way, the effect of obidoxime in the current study should not be
attributed to the aldoximes groups.
According to Cabal et al. (2004), there are other structural fea-
tures like the number of pyridinium rings, the position of the
oxime group in the pyridinium ring and the number of methylene
groups in linking chain between two quaternary pyridinium rings
in the molecule of reactivators that can play an important role in
the reactivating efﬁcacy of oximes. The chain linking the two qua-
ternary nitrogen in bispyridinium oximes exerts a great effect on
the reactivating efﬁcacy, although this part of the oxime reactiva-
tor molecule does not play any role in the dephosphorylation pro-
cess (Kassa et al., 2008). This is in better agreement with our study
since none of the two newly oximes here tested have pyridinium
rings, and they presented results that are comparable to the ones
achieved by pralidoxime, but not to those achieved by obidoxime.
Indeed, oxime 1 had a sulfur (S) atom, which can either act as
reducing or oxidant agent. However, this fact seems to not affect
in great scale the oxime reactivation potency, once that oxime 1
had similar results that oxime 2.
It is clear also that in vitro reactivation of inhibited-AChE does
not depend of oxime concentration. Since reactivation once
achieved by the oxime, an increase on the concentration seems
to not alter the activity of the enzyme, as could be observed for
oxime 2 and pralidoxime at 50 and 100 lM in diazinon-inhibited
AChE, and for oxime 2 and obidoxime at 10 and 50 lM in mala-
thion-inhibited AChE. This may be probably the aging process, gen-
erating an anionic methylphosphonic acid-AChE conjugate that is
no longer susceptible to oxime reactivation because of charge
repulsion between the anionic oximate and methylphosphonic
acid groups (Barak et al., 1997). In this way it seems that the po-
tency of reactivation of an oxime depends not so much on the con-
centration, but must on the time of the exposure of the oxime after
the formation of the complex OP–AChE.
In this study it was not possible to archive a successful reactiva-
tion of the inhibited-BChE, even with the highest oxime concentra-
tion of 100 lM. This result was not unexpected since many oximes
are poor reactivators of BChE than AChE (Worek et al., 1999b). This
may be due to the active site of BChE is larger than that of AChE
(Saxena et al., 1997) and better accommodates phosphorylated
oximes that are generated during reactivation and can then inhibit
the regenerated BChE by blocking it´s active site or by rephosphory-
lating the newly active enzyme.
M.D. Costa et al. / Toxicology in Vitro 25 (2011) 2120–2123 2123In conclusion, our data conﬁrm that both newly developed oxi-
mes seem to be promising reactivators OP-inhibited AChE, with
similar pralidoxime AChE reactivation rates in vitro.Acknowledgments
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